Microbix Biosystems Inc. (MBXBF)
USD 0.27
(10.2%)
USD 0.27
(10.2%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.37 Million CAD | 14.83% |
| 2022 | 5.55 Million CAD | 9.4% |
| 2021 | 5.07 Million CAD | 3.89% |
| 2020 | 4.88 Million CAD | 13.0% |
| 2019 | 4.32 Million CAD | -9.78% |
| 2018 | 4.79 Million CAD | 1.02% |
| 2017 | 4.74 Million CAD | 0.85% |
| 2016 | 4.7 Million CAD | -17.92% |
| 2015 | 5.73 Million CAD | 12.34% |
| 2014 | 5.1 Million CAD | -0.08% |
| 2013 | 5.1 Million CAD | -18.92% |
| 2012 | 6.3 Million CAD | 10.17% |
| 2011 | 5.71 Million CAD | 2.21% |
| 2010 | 5.59 Million CAD | 1.86% |
| 2009 | 5.49 Million CAD | 41.89% |
| 2008 | 3.87 Million CAD | 108.99% |
| 2007 | 1.85 Million CAD | 53.07% |
| 2006 | 1.21 Million CAD | 95.13% |
| 2005 | 620.26 Thousand CAD | 10.85% |
| 2004 | 559.53 Thousand CAD | 93.84% |
| 2003 | 288.65 Thousand CAD | 477.32% |
| 2002 | 50 Thousand CAD | -66.67% |
| 2001 | 150 Thousand CAD | -50.0% |
| 2000 | 300 Thousand CAD | -40.0% |
| 1999 | 500 Thousand CAD | -16.67% |
| 1998 | 600 Thousand CAD | 0.0% |
| 1997 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 5.5 Million CAD | -5.49% |
| 2024 Q2 | 5.82 Million CAD | 1.32% |
| 2024 Q1 | 5.75 Million CAD | 1.24% |
| 2023 FY | 6.37 Million CAD | 14.83% |
| 2023 Q2 | 6.28 Million CAD | 9.35% |
| 2023 Q3 | 6.3 Million CAD | 0.33% |
| 2023 Q1 | 5.74 Million CAD | 3.37% |
| 2023 Q4 | 6.37 Million CAD | 1.26% |
| 2022 FY | 5.55 Million CAD | 9.4% |
| 2022 Q2 | 5.56 Million CAD | 14.03% |
| 2022 Q3 | 5.55 Million CAD | -0.17% |
| 2022 Q1 | 4.88 Million CAD | -3.87% |
| 2022 Q4 | 5.55 Million CAD | -0.03% |
| 2021 Q1 | 4.84 Million CAD | -0.85% |
| 2021 Q2 | 5 Million CAD | 3.18% |
| 2021 Q3 | 4.96 Million CAD | -0.64% |
| 2021 FY | 5.07 Million CAD | 3.89% |
| 2021 Q4 | 5.07 Million CAD | 2.21% |
| 2020 Q1 | 4.9 Million CAD | 13.46% |
| 2020 FY | 4.88 Million CAD | 13.0% |
| 2020 Q3 | 4.83 Million CAD | -1.75% |
| 2020 Q4 | 4.88 Million CAD | 1.1% |
| 2020 Q2 | 4.92 Million CAD | 0.26% |
| 2019 FY | 4.32 Million CAD | -9.78% |
| 2019 Q1 | 4.67 Million CAD | -2.59% |
| 2019 Q2 | 4.55 Million CAD | -2.59% |
| 2019 Q3 | 4.42 Million CAD | -2.67% |
| 2019 Q4 | 4.32 Million CAD | -2.31% |
| 2018 FY | 4.79 Million CAD | 1.02% |
| 2018 Q2 | 4.75 Million CAD | -2.98% |
| 2018 Q3 | 4.69 Million CAD | -1.27% |
| 2018 Q4 | 4.79 Million CAD | 2.07% |
| 2018 Q1 | 4.9 Million CAD | 3.33% |
| 2017 Q4 | 4.74 Million CAD | 10.64% |
| 2017 Q2 | 4.46 Million CAD | -2.14% |
| 2017 FY | 4.74 Million CAD | 0.85% |
| 2017 Q1 | 4.56 Million CAD | -2.96% |
| 2017 Q3 | 4.29 Million CAD | -4.01% |
| 2016 Q2 | 4.89 Million CAD | -10.25% |
| 2016 Q4 | 4.7 Million CAD | -1.91% |
| 2016 Q1 | 5.45 Million CAD | -4.88% |
| 2016 Q3 | 4.79 Million CAD | -1.98% |
| 2016 FY | 4.7 Million CAD | -17.92% |
| 2015 FY | 5.73 Million CAD | 12.34% |
| 2015 Q1 | 5.69 Million CAD | 11.55% |
| 2015 Q4 | 5.73 Million CAD | -0.43% |
| 2015 Q2 | 5.62 Million CAD | -1.19% |
| 2015 Q3 | 5.75 Million CAD | 2.37% |
| 2014 Q4 | 5.1 Million CAD | -16.49% |
| 2014 Q1 | 5.08 Million CAD | -0.38% |
| 2014 FY | 5.1 Million CAD | -0.08% |
| 2014 Q3 | 6.11 Million CAD | 0.58% |
| 2014 Q2 | 6.07 Million CAD | 19.42% |
| 2013 Q2 | 6.41 Million CAD | 0.88% |
| 2013 Q4 | 5.1 Million CAD | -21.14% |
| 2013 Q3 | 6.47 Million CAD | 0.96% |
| 2013 Q1 | 6.36 Million CAD | 0.96% |
| 2013 FY | 5.1 Million CAD | -18.92% |
| 2012 FY | 6.3 Million CAD | 10.17% |
| 2012 Q4 | 6.3 Million CAD | 6.85% |
| 2012 Q3 | 5.89 Million CAD | 1.25% |
| 2012 Q2 | 5.82 Million CAD | 0.98% |
| 2012 Q1 | 5.76 Million CAD | 0.84% |
| 2011 Q2 | 5.72 Million CAD | 0.53% |
| 2011 FY | 5.71 Million CAD | 2.21% |
| 2011 Q4 | 5.71 Million CAD | 0.66% |
| 2011 Q3 | 5.68 Million CAD | -0.68% |
| 2011 Q1 | 5.68 Million CAD | 1.69% |
| 2010 Q3 | 5.64 Million CAD | 0.32% |
| 2010 Q2 | 5.62 Million CAD | 0.57% |
| 2010 Q1 | 5.59 Million CAD | 1.8% |
| 2010 Q4 | 5.59 Million CAD | -0.83% |
| 2010 FY | 5.59 Million CAD | 1.86% |
| 2009 FY | 5.49 Million CAD | 41.89% |
| 2009 Q3 | 5.46 Million CAD | 6.41% |
| 2009 Q4 | 5.49 Million CAD | 0.5% |
| 2009 Q1 | 3.89 Million CAD | 0.6% |
| 2009 Q2 | 5.13 Million CAD | 31.89% |
| 2008 Q2 | 1.85 Million CAD | 0.08% |
| 2008 Q1 | 1.84 Million CAD | -0.21% |
| 2008 FY | 3.87 Million CAD | 108.99% |
| 2008 Q4 | 3.87 Million CAD | 15.14% |
| 2008 Q3 | 3.36 Million CAD | 81.75% |
| 2007 Q4 | 1.85 Million CAD | 3.34% |
| 2007 FY | 1.85 Million CAD | 53.07% |
| 2007 Q1 | 1.51 Million CAD | 25.34% |
| 2007 Q2 | 1.8 Million CAD | 18.69% |
| 2007 Q3 | 1.79 Million CAD | -0.43% |
| 2006 Q4 | 1.21 Million CAD | 8.43% |
| 2006 FY | 1.21 Million CAD | 95.13% |
| 2006 Q2 | 1.11 Million CAD | 52.08% |
| 2006 Q1 | 733.09 Thousand CAD | 18.19% |
| 2006 Q3 | 1.11 Million CAD | 0.12% |
| 2005 Q1 | 567.32 Thousand CAD | 1.39% |
| 2005 Q2 | 575.49 Thousand CAD | 1.44% |
| 2005 FY | 620.26 Thousand CAD | 10.85% |
| 2005 Q4 | 620.26 Thousand CAD | 6.2% |
| 2005 Q3 | 584.07 Thousand CAD | 1.49% |
| 2004 Q3 | 552.12 Thousand CAD | 1.3% |
| 2004 Q2 | 545.06 Thousand CAD | 86.52% |
| 2004 Q4 | 559.53 Thousand CAD | 1.34% |
| 2004 FY | 559.53 Thousand CAD | 93.84% |
| 2004 Q1 | 292.22 Thousand CAD | 1.23% |
| 2003 Q4 | 288.65 Thousand CAD | -42.27% |
| 2003 Q2 | 500 Thousand CAD | -9.09% |
| 2003 Q1 | 550 Thousand CAD | 1000.0% |
| 2003 FY | 288.65 Thousand CAD | 477.32% |
| 2003 Q3 | 500 Thousand CAD | 0.0% |
| 2002 Q3 | 87.5 Thousand CAD | -30.0% |
| 2002 FY | 50 Thousand CAD | -66.67% |
| 2002 Q2 | 125 Thousand CAD | -9.09% |
| 2002 Q1 | 137.5 Thousand CAD | -8.33% |
| 2002 Q4 | 50 Thousand CAD | -42.86% |
| 2001 Q1 | 262.5 Thousand CAD | -12.5% |
| 2001 FY | 150 Thousand CAD | -50.0% |
| 2001 Q3 | 397.58 Thousand CAD | 76.7% |
| 2001 Q4 | 150 Thousand CAD | -62.27% |
| 2001 Q2 | 225 Thousand CAD | -14.29% |
| 2000 FY | 300 Thousand CAD | -40.0% |
| 2000 Q1 | 400 Thousand CAD | -20.0% |
| 2000 Q4 | 300 Thousand CAD | -50.0% |
| 2000 Q3 | 600 Thousand CAD | -14.29% |
| 2000 Q2 | 700 Thousand CAD | 75.0% |
| 1999 Q2 | 500 Thousand CAD | -16.67% |
| 1999 Q4 | 500 Thousand CAD | 0.0% |
| 1999 Q3 | 500 Thousand CAD | 0.0% |
| 1999 Q1 | 600 Thousand CAD | 0.0% |
| 1999 FY | 500 Thousand CAD | -16.67% |
| 1998 Q4 | 600 Thousand CAD | 0.0% |
| 1998 FY | 600 Thousand CAD | 0.0% |
| 1998 Q3 | - CAD | 0.0% |
| 1998 Q2 | - CAD | 0.0% |
| 1998 Q1 | - CAD | 0.0% |
| 1997 Q2 | 500 Thousand CAD | 0.0% |
| 1997 Q3 | - CAD | -100.0% |
| 1997 Q1 | 500 Thousand CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| 1997 Q4 | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 20.9 Million USD | 69.487% |
| Intellipharmaceutics International Inc. | - USD | -Infinity% |
| Evofem Biosciences, Inc. | 8000.00 USD | -79648.8% |
| Santhera Pharmaceuticals Holding AG | 1.75 Million USD | -263.428% |
| Propanc Biopharma, Inc. | 58.64 Thousand USD | -10779.411% |
| Marizyme, Inc. | 667.12 Thousand USD | -856.322% |
| Genus plc | 228.2 Million USD | 97.204% |
| Pharming Group N.V. | 166.1 Million USD | 96.159% |
| Therapeutic Solutions International, Inc. | 5512.00 USD | -115645.718% |
| CNBX Pharmaceuticals Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | 2.21 Million USD | -188.683% |
| RegeneRx Biopharmaceuticals, Inc. | 1.4 Million USD | -354.754% |
| IMV Inc. | 27.39 Million USD | 76.714% |
| AXIM Biotechnologies, Inc. | 5.42 Million USD | -17.57% |
| ONE Bio Corp. | 592.19 Thousand USD | -977.326% |
| RVL Pharmaceuticals plc | 55.61 Million USD | 88.528% |
| Mesoblast Limited | 100.29 Million USD | 93.639% |
| MultiCell Technologies, Inc. | 36.43 USD | -17512675.185% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 2.22 Million USD | -186.608% |
| Genscript Biotech Corporation | 287.12 Million USD | 97.778% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -419.383% |
| Nanobac Pharmaceuticals, Incorporated | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 25.29 Thousand USD | -25118.009% |
| Oncotelic Therapeutics, Inc. | 1.89 Million USD | -236.055% |
| Skye Bioscience, Inc. | 171.23 Thousand USD | -3625.927% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | - USD | -Infinity% |
| Q BioMed Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | 322 Thousand USD | -1881.337% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 11.23 Billion USD | 99.943% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 554.59 Thousand USD | -1050.382% |
| Enzolytics Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 164.2 Thousand USD | -3785.329% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 15.35 Million USD | 58.448% |
| Northwest Biotherapeutics, Inc. | 20.31 Million USD | 68.59% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 150 Thousand USD | -4153.269% |
| Endonovo Therapeutics, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 4456.00 USD | -143075.583% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 126.3 Thousand USD | -4951.309% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2682.449% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 8.26 Million USD | 22.799% |
| Kadimastem Ltd | 229.69 Thousand USD | -2677.603% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 265.63 Thousand USD | -2301.756% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 1064.00 USD | -599515.038% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -4164.243% |
| Regen BioPharma, Inc. | 149.61 Thousand USD | -4164.243% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 445 Thousand USD | -1333.686% |
| CytoDyn Inc. | 141 Thousand USD | -4424.755% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 80 Thousand USD | -7874.88% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 18.415% |
| SYBLEU INC | 300 Thousand USD | -2026.635% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 369.04 Thousand USD | -1628.742% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.15 Million USD | 21.719% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | 457 Thousand USD | -1296.04% |
| Neutra Corp. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 1.16 Million USD | -449.518% |
| PureTech Health plc | 18.25 Million USD | 65.042% |
| Coeptis Therapeutics, Inc. | 150 Thousand USD | -4153.269% |
| IXICO plc | 275 Thousand USD | -2219.965% |
| IntelGenx Technologies Corp. | 11.83 Million USD | 46.111% |
| Gelesis Holdings, Inc. | 26.3 Million USD | 75.75% |
| CSL Limited | 11.23 Billion USD | 99.943% |
| Cellectis S.A. | 36.21 Million USD | 82.381% |